{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:50:43Z","timestamp":1791287443523,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T00:00:00Z","timestamp":1224028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\/Aims: <\/jats:bold> Current knowledge confers a crucial role to connective tissue growth factor (CTGF\/CCN2) in hepatic fibrogenesis. Hepatocytes are likely to be the major cellular source of CTGF in the liver in which CTGF is sensitively upregulated by TGF\u2010\u03b2. Recently, we demonstrated that the methylxanthine derivate caffeine leads to an upregulation of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3) expression in hepatocytes, thus sensitizing these cells to the well\u2010known inhibitory effect of 15\u2010deoxy\u2010\u0394<jats:sup>12,14<\/jats:sup>\u2010prostaglandin J<jats:sub>2<\/jats:sub> (15\u2010d\u2010PGJ<jats:sub>2<\/jats:sub>) on CTGF expression. However, upregulation of the receptor alone is not sufficient <jats:italic>per se<\/jats:italic>; its physiological ligand 15\u2010d\u2010PGJ<jats:sub>2<\/jats:sub> is required to exert an inhibitory effect on transforming growth factor\u2010\u03b2 (TGF\u2010\u03b2) target genes such as CTGF.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> This study compared serum concentrations of 15\u2010d\u2010PGJ<jats:sub>2<\/jats:sub> in Caucasian patients with fibrotic liver diseases (<jats:italic>n<\/jats:italic>=289), Caucasian controls (<jats:italic>n<\/jats:italic>=136) and Caucasian non\u2010liver disease (NLD) sick (<jats:italic>n<\/jats:italic>=307), as well as of Chinese patients with hepatocellular carcinoma (HCC) (<jats:italic>n<\/jats:italic>=43) and Chinese healthy controls (<jats:italic>n<\/jats:italic>=63) in order to characterize their suitability for therapeutic approaches with PPAR\u03b3\u2010inducing (i.e. CTGF inhibitory) drugs such as caffeine.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> The presented data showed that Caucasian patients with ongoing hepatic fibrogenesis (mean 6.2\u00b15.9\u2003\u03bcg\/L) displayed strikingly higher serum concentrations of 15\u2010d\u2010PGJ<jats:sub>2<\/jats:sub> than healthy probands (mean 2.3\u00b11.0) and Caucasian patients with NLD (mean 2.7\u00b11.4\u2003\u03bcg\/L). Similar results were found in Chinese patients with fully developed HCC (mean 1.3\u00b10.7\u2003\u03bcg\/L) compared with Chinese healthy controls (mean 0.4\u00b10.2\u2003\u03bcg\/L).<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> In conclusion, our data thus proposed an increased suitability of these patient groups for therapeutic approaches with drugs inducing PPAR\u03b3 expression, such as methylxanthine derivates.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2008.01895.x","type":"journal-article","created":{"date-parts":[[2009,4,7]],"date-time":"2009-04-07T14:23:36Z","timestamp":1239114216000},"page":"730-735","source":"Crossref","is-referenced-by-count":7,"title":["Elevated concentrations of 15\u2010deoxy\u2010\u0394<sup>12,14<\/sup>\u2010prostaglandin J<sub>2<\/sub> in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor \u03b3\u2010inducing drugs"],"prefix":"10.1111","volume":"29","author":[{"given":"Olav A.","family":"Gressner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Rehbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Lahme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Siluschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel M.","family":"Gressner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,7]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"219","article-title":"Prostaglandin D2","volume":"37","author":"Ito S","year":"1989","journal-title":"a biochemical perspective"},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"16619","DOI":"10.1016\/S0021-9258(18)37435-0","article-title":"Occurrence of 9\u2010deoxy\u2010delta 9, delta 12\u201013,14\u2010dihydroprostaglandin D2 in human urine","volume":"263","author":"Hirata Y","year":"1988","journal-title":"J Biol Chem"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90194-9"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.41.23975"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1550217"},{"key":"e_1_2_7_7_2","first-page":"266","article-title":"The peroxisome proliferator\u2010activated receptors","volume":"804","author":"Forman BM","year":"1996","journal-title":"ligands and activators"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(98)80014-2"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21806"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00260.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.05.015"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm888"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb826"},{"key":"e_1_2_7_14_2","first-page":"973","article-title":"The epithelial\u2013mesenchymal transition","volume":"172","author":"Lee JM","year":"2006","journal-title":"new insights in signaling, development, and disease"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1877"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700194200"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.2110"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.052795"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06721.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06739.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i39.5208"},{"key":"e_1_2_7_22_2","first-page":"133","article-title":"Connective tissue growth factor is directly related to liver fibrosis","volume":"49","author":"Hayashi N","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6346(03)00115-3"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300425"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302929"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.894"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hep.2008.04.010"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2006.00299.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.09.069"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.20819"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-008-9615-8"},{"key":"e_1_2_7_34_2","volume-title":"Classification of Primary Liver Cancer","author":"Liver Cancer Study Group of Japan","year":"1997"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-5926-2-S1-S56"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2003.27"},{"key":"e_1_2_7_37_2","first-page":"1290","article-title":"Restriction enzyme\u2010based method for transforming growth factor\u2010beta(1) genotyping","volume":"45","author":"Lario S","year":"1999","journal-title":"nonisotopic detection of polymorphisms in codons 10 and 25 and the 5\u2032-flanking region"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-8823(03)00080-7"},{"key":"e_1_2_7_39_2","first-page":"1665","article-title":"Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection","volume":"53","author":"Nunez O","year":"2004","journal-title":"role of viral core and NS5A proteins"},{"issue":"1","key":"e_1_2_7_40_2","first-page":"339A","article-title":"The role of PPAR gamma in bile duct ligation\u2010induced hepatic injury in rats","volume":"46","author":"Kitagawa T","journal-title":"Hepatology"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgm026"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02134"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00677.2004"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-005-0057-5"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.05.005"},{"key":"e_1_2_7_46_2","first-page":"L1146","article-title":"PPARgamma agonists inhibit TGF\u2010beta induced pulmonary myofibroblast differentiation and collagen production","volume":"288","author":"Burgess HA","year":"2005","journal-title":"implications for therapy of lung fibrosis"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004263468"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01639.x"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2008.01895.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2008.01895.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T18:50:28Z","timestamp":1697136628000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2008.01895.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,7]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1111\/j.1478-3231.2008.01895.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01895.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,7]]}}}